Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apitolisib - Roche

Next Previous
Drug Profile

Apitolisib - Roche

Alternative Names: G-038390; G-038390.1; GDC-0980; GDC-0980.1; RG-7422

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Piramed
  • Developer Genentech
  • Class Amines; Antineoplastics; Heterocyclic bicyclo compounds; Ketones; Morpholines; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Non-Hodgkin's lymphoma; Prostate cancer; Renal cancer; Solid tumours

Most Recent Events

  • 01 Apr 2016 Genentech completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in USA, Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Italy, South Korea, Malaysia, Mexico, New Zealand, Peru, Russia, Singapore, Spain, Thailand and the UK (NCT01437566)
  • 01 Jun 2015 Genentech completes a phase II trial in Renal cancer (Metastatic disease, Second-line therapy or greater) in USA, France, United Kingdom, Germany and Spain (NCT01442090)
  • 01 Nov 2014 Genentech completes a phase I trial in Non-Hodgkin's lymphoma (Late-stage disease, Second-line therapy or greater) in USA and United Kingdom (NCT00854152)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top